The early acquisition of TP53 mutations in the founding stem cell clone probably contributes to the frequent cytogenetic abnormalities and poor responses to chemotherapy that are typical of patients with t-AML/t-MDS. This evidence concerns the gene TP53 and myelodysplastic syndrome.